ORPHA:100043
Autosomal dominant intermediate Charcot-Marie-Tooth disease type A
Also known as: CMTDIA
Publications
1,509
Trials
0
Interventional, condition-specific
Researchers
114
Distinct authors in sample
Gene link
GBF1
Strong
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare motor and sensory characterized by intermediate motor median nerve conduction velocities (usually between 25 and 45 m/s) and signs of both demyelination and axonal degeneration in nerve biopsies. It presents with usual clinical features of Charcot-Marie-Tooth disease ( muscle weakness and atrophy of the distal extremities, distal sensory loss, reduced or absent deep tendon reflexes, and feet deformities) in the first to second decade of life with steady progression until the fourth decade, severe progression and stabilization afterwards.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011675
- MeSH:C564702
- OMIM:606483
- UMLS:C5561933
Additional Mondo synonyms (3)
CMT2GG · Charcot-Marie-Tooth disease dominant intermediate type A · autosomal dominant intermediate Charcot-Marie-Tooth disease type A
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — GBF1
- LiteraturePresent
1,509 matched papers (923 in last 10 years) Source
- Phenotype characterisedPresent
19 HPO annotations (e.g. Dysarthria; Areflexia; Segmental peripheral demyelination) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GBF1).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
19
Associated phenotypes · MONDO:0011675
- Dysarthria
- Areflexia
- Segmental peripheral demyelination
- Steppage gait
- Pes cavus
Showing 5 of 19 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,509
1,509 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,509 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
923 in the last 10 years · low confidence
Phrase hits: 11 · MeSH hits: 1
Who's working on it?
114
Distinct author names in 11 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Abbasi AA1 paper · 2014
Department of Zoology, University of Azad Jammu and Kashmir, 13100 Muzaffarabad, Pakistan.
Papers in Europe PMC - 02Alexandrova OY1 paper · 2020
Moscow Regional Research and Clinical Institute ("MONIKI"), 129110 Moscow, Russia.
Papers in Europe PMC - 03Ali G1 paper · 2014
Department of Biotechnology, University of Azad Jammu and Kashmir, 13100 Muzaffarabad, Pakistan.
Papers in Europe PMC - 04Andrade DM1 paper · 2014
Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario M5S 2J7, Canada; Krembil Neuroscience Centre, Toronto Western Research Institute, Toronto, Ontario M5S 2J7, Canada.
Papers in Europe PMC - 05Ansar M1 paper · 2014
Department of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Papers in Europe PMC - 06Arakawa M1 paper · 2025
Department of Biological Informatics and Experimental Therapeutics, Graduate School of Medicine, Akita University, Akita, Japan.
Papers in Europe PMC - 07Ayaz M1 paper · 2014
Lahore Institute of Research and Development, Lahore 51000, Pakistan.
Papers in Europe PMC - 08Ayub M1 paper · 2014
Lahore Institute of Research and Development, Lahore 51000, Pakistan; Department of Psychiatry, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Papers in Europe PMC - 09Battaloglu E1 paper · 2007Papers in Europe PMC
- 10Bergmann C1 paper · 2007Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category autosomal dominant intermediate Charcot-Marie-Tooth disease also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: autosomal dominant intermediate Charcot-Marie-Tooth disease
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Autosomal dominant intermediate Charcot-Marie-Tooth disease type A — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Autosomal dominant intermediate Charcot-Marie-Tooth disease type A" OR "CMTDIA" OR "CMT2GG" OR "Charcot-Marie-Tooth disease dominant intermediate type A") OR (MESH:"Charcot-Marie-Tooth Disease, Dominant Intermediate A") OR ("GBF1" OR "GBF1 syndrome" OR "GBF1-related")MeSH descriptor terms unioned into the query: Charcot-Marie-Tooth Disease, Dominant Intermediate A
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Autosomal dominant intermediate Charcot-Marie-Tooth disease type A" OR "CMTDIA" OR "CMT2GG" OR "Charcot-Marie-Tooth disease dominant intermediate type A" OR "Charcot-Marie-Tooth Disease, Dominant Intermediate A"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"autosomal dominant intermediate Charcot-Marie-Tooth disease"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1509) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T06:56:16.340Z